Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 284 participants.

Also called NCT01841762

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 284 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01841762
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01841762. Allocation not applicable; no masking; primary purpose treatment. Start 2013-04-01 (actual); primary completion 2015-11-01 (actual). Results posted on 2018-10-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Macitentan
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct01841762
Content hash
cb6b285160581c40054084ef1423bab8cc64675a18cf0874863abe7f45147c3b